tetano
Editor, Senior Moderator
Eur J Hosp Pharm
. 2020 Nov 20;ejhpharm-2020-002476.
doi: 10.1136/ejhpharm-2020-002476. Online ahead of print.
Prescription profile in patients with SARS-CoV-2 infection hospitalised in Aragon, Spain
Adriana Alvarez[SUP] 1 [/SUP], Laura Cabia[SUP] 2 [/SUP], Cristina Trigo[SUP] 1 [/SUP], Ana Cristina Bandr?s[SUP] 1 [/SUP], Mar?a Bestu?[SUP] 1 [/SUP]
Affiliations
Abstract
Introduction: On 14 March 2020, a state of alarm was declared in Spain because of the pandemic of coronavirus disease (COVID-19). After 12 weeks from the beginning of the pandemic, the number of confirmed cases stoods at 5781 in Aragon: 46% hospitalised, 5% admitted to intensive care unit, and 15% died. The absence of controlled trials in SARS-CoV-2 infection and the fast progression of the disease has promoted the use of treatments with unproven potential benefit. The objective of this study is to define the prescription profile in patients with SARS-CoV-2 infection hospitalised in Aragon, Spain during the pandemic and its adaptation to the official recommendations.
Patients and methods: Descriptive retrospective study of the consumption and inpatient dispensation of drugs in a sample of COVID-19 infected inpatients (with positive PCR test result) admitted to hospitals of Aragon, between 1 March and 8 May 2020. Data were collected by an inpatient dispensation software program.
Results: 1482 positive COVID-19 patients were analysed: 54.9% male, median age 75 years (IQR 62-85); 12% were admitted to the intensive care unit. Median prescription: 13 active ingredients per patient (IQR 9-19). 73% (1093 patients) received hydroxychloroquine, lopinavir/ritonavir, or azithromycin, 81% as combination therapy. 4.3% (52) received other antivirals. 46% received corticosteroids (84% methylprednisolone, 8.7% dexamethasone) and 2.2% tocilizumab.
Discussion: At the time of the study period there was not enough quality evidence to issue a recommendation on any treatment. There are several clinical trials ongoing to clarify what is the best treatment for patient with SARS-CoV-2 infection.
Keywords: case reports; complementary therapies; documentation; emergency medicine; evidence-based medicine; safety.
. 2020 Nov 20;ejhpharm-2020-002476.
doi: 10.1136/ejhpharm-2020-002476. Online ahead of print.
Prescription profile in patients with SARS-CoV-2 infection hospitalised in Aragon, Spain
Adriana Alvarez[SUP] 1 [/SUP], Laura Cabia[SUP] 2 [/SUP], Cristina Trigo[SUP] 1 [/SUP], Ana Cristina Bandr?s[SUP] 1 [/SUP], Mar?a Bestu?[SUP] 1 [/SUP]
Affiliations
- PMID: 33219011
- DOI: 10.1136/ejhpharm-2020-002476
Abstract
Introduction: On 14 March 2020, a state of alarm was declared in Spain because of the pandemic of coronavirus disease (COVID-19). After 12 weeks from the beginning of the pandemic, the number of confirmed cases stoods at 5781 in Aragon: 46% hospitalised, 5% admitted to intensive care unit, and 15% died. The absence of controlled trials in SARS-CoV-2 infection and the fast progression of the disease has promoted the use of treatments with unproven potential benefit. The objective of this study is to define the prescription profile in patients with SARS-CoV-2 infection hospitalised in Aragon, Spain during the pandemic and its adaptation to the official recommendations.
Patients and methods: Descriptive retrospective study of the consumption and inpatient dispensation of drugs in a sample of COVID-19 infected inpatients (with positive PCR test result) admitted to hospitals of Aragon, between 1 March and 8 May 2020. Data were collected by an inpatient dispensation software program.
Results: 1482 positive COVID-19 patients were analysed: 54.9% male, median age 75 years (IQR 62-85); 12% were admitted to the intensive care unit. Median prescription: 13 active ingredients per patient (IQR 9-19). 73% (1093 patients) received hydroxychloroquine, lopinavir/ritonavir, or azithromycin, 81% as combination therapy. 4.3% (52) received other antivirals. 46% received corticosteroids (84% methylprednisolone, 8.7% dexamethasone) and 2.2% tocilizumab.
Discussion: At the time of the study period there was not enough quality evidence to issue a recommendation on any treatment. There are several clinical trials ongoing to clarify what is the best treatment for patient with SARS-CoV-2 infection.
Keywords: case reports; complementary therapies; documentation; emergency medicine; evidence-based medicine; safety.